Renalytix Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 85.00 7 01:00:00
Bid Price Offer Price High Price Low Price Open Price
80.00 90.00 85.00 85.00 85.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Services, Nec 2.97 -56.73 -75.90 - 79.71
Last Trade Time Trade Type Trade Size Trade Price Currency
10:14:07 O 7 88.10 GBX

Renalytix (RENX) Latest News

Renalytix (RENX) Discussions and Chat

Renalytix (RENX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Renalytix (RENX) Top Chat Posts

Top Posts
Posted at 19/5/2023 20:23 by 1jat
Wan…..I am of a similar view…this GM is getting the house in order for a fund raise.
We know one is needed (bar a miraculous explosion in paid for tests)…
The price new funds can be raised at will largely be driven by the FDA opinion….
There is scope for the large investors with an inside track in the fund raise to dilute existing SH on disadvantageous terms….but that does guarantee the funds can be raised quickly and easily (assuming they are onboard).

Now is a very risky time to add as rejection could be a fatal blow…..safer, but perhaps less rewarding to wait for the raise to be announced….and completed.

Posted at 10/5/2023 09:42 by wan
Interesting commentary from Davita's earnings call for the period ending March 31, 2023.

Excerpt from Q1 2023 Earnings Call
May 08, 2023, 5:00 p.m. ET

On April 1, DaVita and Medtronic announced the launch of Mozarc Medical, a new independent device company focused exclusively on innovative kidney health technologies. Mozarc's current products and its R&D pipeline ranging from kidney access technologies to advanced home dialysis and acute therapies are intended to improve the overall patient experience and increased access to home-based care. This investment reaffirms our commitment to realizing scale transformation in kidney care and allow us to fuel innovation in partnership with Medtronic, a global leader in healthcare technology. And finally, a note on Integrated Kidney Care, or IKC.

We continue to make progress consistent with our business plan and demonstrate that our model of care is improving the health and well-being of our patients. I'll highlight two examples of this. First, across our IKC program, more than half of our patients achieved an optimal start, which means that patient initiates dialysis treatment at home or appropriate vascular access in place. Optimal starts reduced costly and difficult hospitalization and on average, leads to a reduction in the continuing cost of care in the month and year that follow.

Second, recent data continued to show an encouraging differentiation in hospitalization rates from patients in our IKC program versus our overall patient population. As we continue to scale our IKC business, which is measured by the total dollars of medical spend in our program, we will continue to focus on driving our net saving rate while pursuing a cost-efficient model of care. In summary, looking across our most important operating metrics, we're seeing progress at a faster rate than assumed in our initial forecast. Therefore, we are revising our adjusted operating income range of $1.4 billion to $1.6 billion to a range of $1.475 billion to $1.625 billion and revising our adjusted earnings per share range of $5.45 to $6.95 to a range of $6.20 to $7.30.
Full transcript - hTTps://

Posted at 21/4/2023 05:35 by mrmarmalade
Hi Wan...I really appreciate the work you put in here keeping us informed good or bad. I was wondering if there was a Telegram channel for RENX?

Posted at 21/3/2023 15:26 by angus17
what we need to give this a boost is a trading update so that we can see what sales are doing. It's a dramatic fall the share price has had in a few weeks and I guess the BOD will be desperate to get it above the recent placing price. I am hoping that those that bought in at the recent placing price have been told that some good news is pending.
Posted at 14/2/2023 13:46 by apatel21
Share price strength here is encouraging given the price placing was done at.Normally see price head south towards placing price.I think Renx has been leaky in the past - is it therefore an indicator of some good news to come ?
Posted at 09/1/2023 12:08 by 1jat
I feel the importance of this announcement is that it demonstrates a path to significantly higher revenues which will allow funding to be raised with less dilution than would otherwise be the case.
The path to positive cash flow is still not absolutely clear and I do expect a fund raising during 2023….if that is around the prevailing share price it will be the time to buy with much reduced downside potential.

Posted at 10/11/2022 19:44 by mikemine1
It seems that the insurance companies are way ahead of the FDA.

I heard from another source that the FDA staff were burnt out due to the pressure to fast track covid related products during the covid scare. The workload increased dramatically and some staff hardly got time off. Rotation and new staff(inexperienced) have been drafted in and in many cases the validations have started all over again. Inevitable this has slowed things down and has led to backlogs.

I have no idea if this is what happened in RENX's case but it certainly fits what we have seen.

The case for RENX must be very strong or all these companies and institutions would not have been so eager to sign up. Personally, I have no doubt that FDA approval will come in Q1. Whether this turns the share price round is anybody's guess but it wouldn't be a negative that's for sure.

Posted at 18/9/2022 11:16 by mikemine1
Despite your last points, I didn't immediately see any relevance to RENX. It was more for the Trellus BB but you had already posted there. Reading it again, I see why you posted it here.

The importance of early diagnosis, or at least warning signs, shouldn't need re-stating but it does it seems. Early detection of problems by tests are often critical and are what clinicians are always desperately seeking, KidneyintelX just one of the new breed now joined by CDPATH. Older tests that come in at a more established stage of a disease will quickly become obsolete and discarded, leaving the companies that own them having a bare cupboard and exposed. They will be forced in to collaboration or ownership of the likes of RENX and Takeda just to stay in the game.

The point about Big Pharma's paying for the test is well spotted. This could be used whilst waiting for the insurance companies to agree to pay for the tests. Fortunately RENX have gone beyond this and have multiple agreements with insurance companies and institutions to pay for the tests which are now being increasingly used by clinicians. RENX are focusing on 3 key geographical areas where the insurance coverage is the most concentrated and it'll be interesting to hear of their progress there. The lack of FDA approval is no hindrance to RENX's ability sell to, promote within or infiltrate the medical establishment. A point vehemently made by McCullough in the last video.

I know you know all this but I thought I'd put it down here to clarify my thoughts and perhaps remind others of the enormity of what RENX has in the field of Renal medicine. They need another 6-9 months to really established themselves as what they should be IMHO but, in the meantime, their quarterly updates should show increasing revenue and penetration of the market. The market will not be able to ignore that.It's more or less what McCullough said.

Posted at 30/6/2022 14:02 by idomeneo

The trouble is, this board is an echo chamber - it's typical for all ADVFN boards. The busiest board are for the worst pie-in-the-sky stocks. I thought that RENX might have something, but could see that progress in sales was slow and the general market was poor. The trouble is, if you ask questions you get shouted down. I thought they might run out of money (reply: "It's complete nonsense to suggest RENX will run out of money") when the share price was > £2.40. My main concern was the bear market and the Ukraine situation. And experience tells me that when stocks are going down then finance dries up. I'm surprised at the apparent industrial scale of lying that the board appear to have indulged in. As I've said before, if the doctors at Mount Sinai could see it working then the word would have spread the word and the share price would have at least flat-lined.

Posted at 25/6/2022 11:59 by 74tom
Hi Wan,

Thanks for your recent posts - you do a great job of trying to join all of the dots!

Your last post combined with the previous one on DaVita / Fresenius summarises why it is an incredibly complex picture at present. Renalytix are in the picture, however it's so difficult to say with any precision exactly where they stand.

Take the opening salvo from their own AZN collaboration PR almost 2 years ago;

"NEW YORK, August 21, 2020 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the collaboration will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to examine further improving outcomes for patients with chronic kidney disease (CKD) and its complications, in coordination with the Mount Sinai Health System. The goal of the first stage is to help improve guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software."

"Results from the program are anticipated in early 2021."

However here we are in mid 2022 and no further news has been released. Same goes for the DaVita partnership which was supposed to launch in 2022. Positive updates on either of them would likely be enough to kick start a share price recovery.

So I ask myself what is holding them back? Is it a case of focusing all of their resources on completing the FDA process & scaling up testing revenues from KidneyIntelx in the VA / Sinai / other health systems whilst putting the other partnerships to one side for the moment?

I note that recently the CEO said something like 'our biggest risk at present is getting distracted', so that suggests this could be the case.

My honest view right now is that RENX is an enigma to 99% of the market. I'm hopeful that the call this week will start to provide some answers but we've been here for some time so I won't hold my breath.

At least the US healthcare sector is showing signs of life at long last & the RNLX share price closed at $4.70 yesterday (equivalent to £1.90)

Renalytix share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230530 10:05:43